 Immunotherapy
"Immunotherapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection.
| Descriptor ID |
D007167
|
| MeSH Number(s) |
E02.095.465.425
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Immunotherapy".
Below are MeSH descriptors whose meaning is more specific than "Immunotherapy".
This graph shows the total number of publications written about "Immunotherapy" by people in UAMS Profiles by year, and whether "Immunotherapy" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2020 | 1 | 1 | 2 | | 2019 | 5 | 4 | 9 | | 2018 | 1 | 1 | 2 | | 2017 | 6 | 5 | 11 | | 2016 | 2 | 4 | 6 | | 2015 | 2 | 1 | 3 | | 2014 | 6 | 1 | 7 | | 2013 | 1 | 1 | 2 | | 2012 | 2 | 1 | 3 | | 2011 | 8 | 2 | 10 | | 2010 | 1 | 2 | 3 | | 2009 | 3 | 4 | 7 | | 2008 | 0 | 2 | 2 | | 2007 | 2 | 0 | 2 | | 2006 | 1 | 1 | 2 | | 2005 | 6 | 3 | 9 | | 2004 | 2 | 3 | 5 | | 2003 | 4 | 3 | 7 | | 2002 | 2 | 2 | 4 | | 2001 | 4 | 1 | 5 | | 2000 | 1 | 2 | 3 | | 1999 | 0 | 1 | 1 | | 1998 | 3 | 2 | 5 | | 1997 | 0 | 1 | 1 | | 1996 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Immunotherapy" by people in Profiles over the past ten years.
-
Mineo M, Lyons SM, Zdioruk M, von Spreckelsen N, Ferrer-Luna R, Ito H, Alayo QA, Kharel P, Giantini Larsen A, Fan WY, Auduong S, Grauwet K, Passaro C, Khalsa JK, Shah K, Reardon DA, Ligon KL, Beroukhim R, Nakashima H, Ivanov P, Anderson PJ, Lawler SE, Chiocca EA. Tumor Interferon Signaling Is Regulated by a lncRNA INCR1 Transcribed from the PD-L1 Locus. Mol Cell. 2020 06 18; 78(6):1207-1223.e8.
-
Arend RC, Beer HM, Cohen YC, Berlin S, Birrer MJ, Campos SM, Rachmilewitz Minei T, Harats D, Wall JA, Foxall ME, Penson RT. Ofranergene obadenovec (VB-111) in platinum-resistant ovarian cancer; favorable response rates in a phase I/II study are associated with an immunotherapeutic effect. Gynecol Oncol. 2020 06; 157(3):578-584.
-
Banaszek A, Bumm TGP, Nowotny B, Geis M, Jacob K, Wölfl M, Trebing J, Kucka K, Kouhestani D, Gogishvili T, Krenz B, Lutz J, Rasche L, Hönemann D, Neuweiler H, Heiby JC, Bargou RC, Wajant H, Einsele H, Riethmüller G, Stuhler G. On-target restoration of a split T cell-engaging antibody for precision immunotherapy. Nat Commun. 2019 11 26; 10(1):5387.
-
Davis LE, Shalin SC, Tackett AJ. Current state of melanoma diagnosis and treatment. Cancer Biol Ther. 2019; 20(11):1366-1379.
-
Yeung TL, Leung CS, Yip KP, Sheng J, Vien L, Bover LC, Birrer MJ, Wong STC, Mok SC. Anticancer Immunotherapy by MFAP5 Blockade Inhibits Fibrosis and Enhances Chemosensitivity in Ovarian and Pancreatic Cancer. Clin Cancer Res. 2019 11 01; 25(21):6417-6428.
-
Kohler H, Pashov A, Kieber-Emmons T. The Promise of Anti-idiotype Revisited. Front Immunol. 2019; 10:808.
-
Kieber-Emmons T. Commentary: Metabolism Impact on Immunotherapy. Monoclon Antib Immunodiagn Immunother. 2019 04; 38(2):37.
-
Rasche L, Kortüm KM, Raab MS, Weinhold N. The Impact of Tumor Heterogeneity on Diagnostics and Novel Therapeutic Strategies in Multiple Myeloma. Int J Mol Sci. 2019 Mar 12; 20(5).
-
Gandhi UH, Cornell RF, Lakshman A, Gahvari ZJ, McGehee E, Jagosky MH, Gupta R, Varnado W, Fiala MA, Chhabra S, Malek E, Mansour J, Paul B, Barnstead A, Kodali S, Neppalli A, Liedtke M, Narayana S, Godby KN, Kang Y, Kansagra A, Umyarova E, Scott EC, Hari P, Vij R, Usmani SZ, Callander NS, Kumar SK, Costa LJ. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019 09; 33(9):2266-2275.
-
Ghobrial I, Cruz CH, Garfall A, Shah N, Munshi N, Kaufman J, Boise LH, Morgan G, Adalsteinsson VA, Manier S, Pillai R, Malavasi F, Lonial S. Immunotherapy in Multiple Myeloma: Accelerating on the Path to the Patient. Clin Lymphoma Myeloma Leuk. 2019 06; 19(6):332-344.
-
Cannon MJ, Block MS, Morehead LC, Knutson KL. The evolving clinical landscape for dendritic cell vaccines and cancer immunotherapy. Immunotherapy. 2019 02; 11(2):75-79.
-
Atiq SO, Atiq OO, Atiq MO, Phillips KC, Jacks BB, Moreno M, Maraboyina S, Atiq OT. The Role of Immunotherapy and Radiation Therapy in Tumor Chemosensitivity in Advanced Head and Neck Cancer. Am J Case Rep. 2018 Oct 18; 19:1241-1244.
-
Tallarico M, Foster JC, Seisler D, Lafky JM, Hurria A, Jatoi A, Cohen HJ, Muss HB, Bartlett N, Cheson BD, Jung SH, Leonard JP, Byrd JC, Nabhan C. Frequency and impact of grade three or four toxicities of novel agents on outcomes of older patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma (alliance A151611). J Geriatr Oncol. 2018 07; 9(4):321-328.
-
Davies FE. Is molecular remission the goal of multiple myeloma therapy? Hematology Am Soc Hematol Educ Program. 2017 12 08; 2017(1):205-211.
-
Byrd TT, Fousek K, Pignata A, Szot C, Samaha H, Seaman S, Dobrolecki L, Salsman VS, Oo HZ, Bielamowicz K, Landi D, Rainusso N, Hicks J, Powell S, Baker ML, Wels WS, Koch J, Sorensen PH, Deneen B, Ellis MJ, Lewis MT, Hegde M, Fletcher BS, St Croix B, Ahmed N. TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer. Cancer Res. 2018 01 15; 78(2):489-500.
-
Jones SM, Burks AW. Food Allergy. N Engl J Med. 2017 09 21; 377(12):1168-1176.
-
Jevtic S, Sengar AS, Salter MW, McLaurin J. The role of the immune system in Alzheimer disease: Etiology and treatment. Ageing Res Rev. 2017 Nov; 40:84-94.
-
Chari A, Arinsburg S, Jagannath S, Satta T, Treadwell I, Catamero D, Morgan G, Feng H, Uhlar C, Khan I, Doshi P, Usmani S. Blood Transfusion Management and Transfusion-Related Outcomes in Daratumumab-Treated Patients With Relapsed or Refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2018 01; 18(1):44-51.
-
Lee DE, Clark AK, Tran KA, Shi VY. New and emerging targeted systemic therapies: a new era for atopic dermatitis. J Dermatolog Treat. 2018 Jun; 29(4):364-374.
-
Mahmoud F, Shields B, Makhoul I, Avaritt N, Wong HK, Hutchins LF, Shalin S, Tackett AJ. Immune surveillance in melanoma: From immune attack to melanoma escape and even counterattack. . 2017 Jul 03; 18(7):451-469.
-
Rasche L, Weinhold N, Morgan GJ, van Rhee F, Davies FE. Immunologic approaches for the treatment of multiple myeloma. Cancer Treat Rev. 2017 Apr; 55:190-199.
-
Mahmoud F, Wilkinson JT, Gizinski A, Viswamitra S, Gokden N, Vander Schilden J. Could knee inflammatory synovitis be induced by pembrolizumab? J Oncol Pharm Pract. 2018 Jul; 24(5):389-392.
-
Jethava Y, Guru Murthy GS, Hamadani M. Relapse of Hodgkin lymphoma after autologous transplantation: Time to rethink treatment? Hematol Oncol Stem Cell Ther. 2017 Jun; 10(2):47-56.
-
Morgan GJ, Jones JR. Integration of Genomics Into Treatment: Are We There Yet? Am Soc Clin Oncol Educ Book. 2017; 37:569-574.
-
Rodriguez A, Tatter SB. Laser Ablation of Recurrent Malignant Gliomas: Current Status and Future Perspective. Neurosurgery. 2016 Dec; 79 Suppl 1:S35-S39.
-
Firwana B, Ravilla R, Raval M, Hutchins L, Mahmoud F. Sarcoidosis-like syndrome and lymphadenopathy due to checkpoint inhibitors. J Oncol Pharm Pract. 2017 Dec; 23(8):620-624.
-
Atrash S, Makhoul I, Mizell JS, Hutchins L, Mahmoud F. Response of metastatic mucosal melanoma to immunotherapy: It can get worse before it gets better. J Oncol Pharm Pract. 2017 Apr; 23(3):215-219.
-
Wootla B, Watzlawik JO, Stavropoulos N, Wittenberg NJ, Dasari H, Abdelrahim MA, Henley JR, Oh SH, Warrington AE, Rodriguez M. Recent Advances in Monoclonal Antibody Therapies for Multiple Sclerosis. Expert Opin Biol Ther. 2016 06; 16(6):827-839.
-
Thanendrarajan S, Davies FE, Morgan GJ, Schinke C, Mathur P, Heuck CJ, Zangari M, Epstein J, Yaccoby S, Weinhold N, Barlogie B, van Rhee F. Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going? Immunotherapy. 2016; 8(3):367-84.
-
Yared JA, Hardy N, Singh Z, Hajj S, Badros AZ, Kocoglu M, Yanovich S, Sausville EA, Ujjani C, Ruehle K, Goecke C, Landau M, Rapoport AP. Major clinical response to nivolumab in relapsed/refractory Hodgkin lymphoma after allogeneic stem cell transplantation. Bone Marrow Transplant. 2016 06; 51(6):850-2.
-
Hambuchen MD, Carroll FI, Rüedi-Bettschen D, Hendrickson HP, Hennings LJ, Blough BE, Brieaddy LE, Pidaparthi RR, Owens SM. Combining Active Immunization with Monoclonal Antibody Therapy To Facilitate Early Initiation of a Long-Acting Anti-Methamphetamine Antibody Response. J Med Chem. 2015 Jun 11; 58(11):4665-77.
-
Smith SG, Koppolu BP, Ravindranathan S, Kurtz SL, Yang L, Katz MD, Zaharoff DA. Intravesical chitosan/interleukin-12 immunotherapy induces tumor-specific systemic immunity against murine bladder cancer. Cancer Immunol Immunother. 2015 Jun; 64(6):689-96.
-
Kieber-Emmons T, Pennisi A, Lane A, Siegel E, Cannon M, Monzavi-Karbassi B, Makhoul I. Defining and managing expectations for early immunotherapy cancer trials. Rev Recent Clin Trials. 2015; 10(1):47-60.
-
Goldman S, Smith L, Galardy P, Perkins SL, Frazer JK, Sanger W, Anderson JR, Gross TG, Weinstein H, Harrison L, Shiramizu B, Barth M, Cairo MS. Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report. Br J Haematol. 2014 Nov; 167(3):394-401.
-
Murali R, Kieber-Emmons T. Cancer immunotherapeutics: evolution of monoclonal antibodies to peptide immunogens. Monoclon Antib Immunodiagn Immunother. 2014 Jun; 33(3):179-82.
-
Steplewski Z, Kieber-Emmons T. Hilary Koprowski, MD: A lifetime of work. Monoclon Antib Immunodiagn Immunother. 2014 Jun; 33(3):1-43.
-
Kosten TR, Domingo CB, Shorter D, Orson F, Green C, Somoza E, Sekerka R, Levin FR, Mariani JJ, Stitzer M, Tompkins DA, Rotrosen J, Thakkar V, Smoak B, Kampman K. Vaccine for cocaine dependence: a randomized double-blind placebo-controlled efficacy trial. Drug Alcohol Depend. 2014 Jul 01; 140:42-7.
-
Hegde M, Bielamowicz KJ, Ahmed N. Novel approaches and mechanisms of immunotherapy for glioblastoma. Discov Med. 2014 Mar; 17(93):145-54.
-
Kaffenberger BH, Lee GL, Tyler K, Chan DV, Jarjour W, Ariza ME, Williams MV, Wong HK. Current and potential immune therapies and vaccines in the management of psoriasis. Hum Vaccin Immunother. 2014; 10(4):876-86.
-
Batchu RB, Gruzdyn OV, Moreno-Bost AM, Szmania S, Jayandharan G, Srivastava A, Kolli BK, Weaver DW, van Rhee F, Gruber SA. Efficient lysis of epithelial ovarian cancer cells by MAGE-A3-induced cytotoxic T lymphocytes using rAAV-6 capsid mutant vector. Vaccine. 2014 Feb 12; 32(8):938-43.
-
Stevens MW, Tawney RL, West CM, Kight AD, Henry RL, Owens SM, Gentry WB. Preclinical characterization of an anti-methamphetamine monoclonal antibody for human use. MAbs. 2014 Mar-Apr; 6(2):547-55.
-
Jain P, Benjamini O, Konoplev S, Mohamed MS, Romo CG, Estrov Z. Spontaneous remission of chemo-immunotherapy related, non-transplant Epstein-Barr virus-associated lymphoproliferative disorder in a patient with chronic lymphocytic leukemia. Leuk Lymphoma. 2013 Nov; 54(11):2540-2.
-
Bird JA, Kulis M, Burk CM, Vickery BP, Jones SM, Burks W. Tree nut- and sesame-specific IgE do not decrease from baseline with peanut oral immunotherapy (OIT). Ann Allergy Asthma Immunol. 2012 Dec; 109(6):470-1.
-
Kaffenberger BH, Wong HK, Jarjour W, Andritsos LA. Remission of psoriasis after allogeneic, but not autologous, hematopoietic stem-cell transplantation. J Am Acad Dermatol. 2013 Mar; 68(3):489-92.
-
Evans CH, Liu F, Porter RM, O'Sullivan RP, Merghoub T, Lunsford EP, Robichaud K, Van Valen F, Lessnick SL, Gebhardt MC, Wells JW. EWS-FLI-1-targeted cytotoxic T-cell killing of multiple tumor types belonging to the Ewing sarcoma family of tumors. Clin Cancer Res. 2012 Oct 01; 18(19):5341-51.
-
Wong HK, Mishra A, Hake T, Porcu P. Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome). Br J Haematol. 2011 Oct; 155(2):150-66.
-
Chiriva-Internati M, Mirandola L, Yu Y, Jenkins MR, Gornati R, Bernardini G, Gioia M, Chiaramonte R, Cannon MJ, Kast WM, Cobos E. Cancer testis antigen, ropporin, is a potential target for multiple myeloma immunotherapy. J Immunother. 2011 Jul-Aug; 34(6):490-9.
-
Enns LL, Evans MS. Intralesional immunotherapy with Candida antigen for the treatment of molluscum contagiosum in children. Pediatr Dermatol. 2011 May-Jun; 28(3):254-8.
-
Chiriva-Internati M, Yu Y, Mirandola L, D'Cunha N, Hardwicke F, Cannon MJ, Cobos E, Kast WM. Identification of AKAP-4 as a new cancer/testis antigen for detection and immunotherapy of prostate cancer. Prostate. 2012 Jan; 72(1):12-23.
-
Chiriva-Internati M, Cobos E, Cannon MJ. Prospects and challenges for immunotherapy of ovarian cancer--what can we learn from the tumor microenvironment? Int Rev Immunol. 2011 Apr-Jun; 30(2-3):67-70.
-
Chiriva-Internati M, Mirandola L, Kast WM, Jenkins MR, Cobos E, Cannon MJ. Understanding the cross-talk between ovarian tumors and immune cells: mechanisms for effective immunotherapies. Int Rev Immunol. 2011 Apr-Jun; 30(2-3):71-86.
-
Varshney P, Jones SM, Scurlock AM, Perry TT, Kemper A, Steele P, Hiegel A, Kamilaris J, Carlisle S, Yue X, Kulis M, Pons L, Vickery B, Burks AW. A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response. J Allergy Clin Immunol. 2011 Mar; 127(3):654-60.
-
Morales AE, Thrailkill KM. GAD-alum immunotherapy in Type 1 diabetes mellitus. Immunotherapy. 2011 Mar; 3(3):323-32.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|